Skip to content
Cultural Foundation
Author:
AlzeCure Pharma
AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million
April 26, 2026
Last Patient has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856
April 20, 2026
←
Previous Page
1
2
3